Trials / Completed
CompletedNCT01018784
A Study of MORAb-009 in Patients With Solid Tumor
A Phase 1 Study of MORAb-009 in Patients With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb-009 | MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-05-01
- Completion
- 2013-02-01
- First posted
- 2009-11-25
- Last updated
- 2016-01-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01018784. Inclusion in this directory is not an endorsement.